PDF(Pubmed)
Abstract：
UNASSIGNED: Lymphedema is a major public health issue for many women undergoing breast cancer treatment. Although weight loss has been reported to be beneficial in the treatment of lymphedema, no studies to date have examined the use of GLP-1RAs for the treatment of secondary lymphedema. This case report describes a patient who experienced significant resolution of her breast cancer-related lymphedema after initiation of a GLP-1RA for weight loss.
UNASSIGNED: Nine months postoperatively the patient developed arm swelling and disability. While on adjuvant chemo and hormonal therapy, her weight increased dramatically and peaked 4 years later. Corresponding to her weight gain was significant worsening of her symptoms.
UNASSIGNED: Due to adjuvant cancer-related weight gain and inability to lose weight with diet and exercise, she was referred for evaluation and diagnosed with lymphedema. The patient started treatment with a Glucagon-like peptide 1 receptor agonist and lost 24% of her body weight over the next 13 months. The improvement in her lymphedema mirrored her weight loss. Her limb volume difference dropped from 10.3% down to 3.4% and she no longer required a compression garment. Her imaging demonstrated return of lymphatic pumping and she experienced a significant improvement in quality of life, assessed by a validated lymphedema-specific patient reported outcome (PROM). She remains on hormonal therapy, no longer needs compression and is back to regular exercise without impairment.
UNASSIGNED: GLP-1 RAs provide a potential medical option for many patients struggling with weight gain and lymphedema. We have observed by all objective measures a significant reduction in lymphedema and the elimination of compression in the case presented as a direct result of GLP-1 RA. This may also reduce a patient\'s BMI to the point where they become a good candidate for lymphovenous bypass or vascularized lymph node transplant when indicated.
UNASSIGNED: Nine months postoperatively the patient developed arm swelling and disability. While on adjuvant chemo and hormonal therapy, her weight increased dramatically and peaked 4 years later. Corresponding to her weight gain was significant worsening of her symptoms.
UNASSIGNED: Due to adjuvant cancer-related weight gain and inability to lose weight with diet and exercise, she was referred for evaluation and diagnosed with lymphedema. The patient started treatment with a Glucagon-like peptide 1 receptor agonist and lost 24% of her body weight over the next 13 months. The improvement in her lymphedema mirrored her weight loss. Her limb volume difference dropped from 10.3% down to 3.4% and she no longer required a compression garment. Her imaging demonstrated return of lymphatic pumping and she experienced a significant improvement in quality of life, assessed by a validated lymphedema-specific patient reported outcome (PROM). She remains on hormonal therapy, no longer needs compression and is back to regular exercise without impairment.
UNASSIGNED: GLP-1 RAs provide a potential medical option for many patients struggling with weight gain and lymphedema. We have observed by all objective measures a significant reduction in lymphedema and the elimination of compression in the case presented as a direct result of GLP-1 RA. This may also reduce a patient\'s BMI to the point where they become a good candidate for lymphovenous bypass or vascularized lymph node transplant when indicated.
摘要：
淋巴水肿是许多接受乳腺癌治疗的妇女的主要公共卫生问题。虽然据报道体重减轻对淋巴水肿的治疗有益，迄今为止,尚无研究检查GLP-1RAs用于继发性淋巴水肿的治疗.该病例报告描述了一名患者，在开始GLP-1RA减肥后，她的乳腺癌相关淋巴水肿明显消退。
■术后9个月，患者出现手臂肿胀和残疾。在进行辅助化疗和激素治疗时，她的体重急剧增加，4年后达到顶峰。与她的体重增加相对应的是她的症状的显著恶化。
■由于与癌症相关的辅助性体重增加以及无法通过饮食和运动来减肥，她被转诊接受评估，并被诊断患有淋巴水肿。患者开始使用胰高血糖素样肽1受体激动剂治疗，在接下来的13个月内体重下降了24％。淋巴水肿的改善反映了她的体重减轻。她的肢体体积差异从10.3％下降到3.4％，她不再需要压缩服。她的影像学表现为淋巴泵的恢复，并且生活质量得到了显着改善，由经过验证的淋巴水肿特异性患者报告的结果（PROM）评估。她还在接受荷尔蒙疗法,不再需要压缩，回到正常运动而没有损伤。
GLP-1RA为许多体重增加和淋巴水肿的患者提供了潜在的医疗选择。在GLP-1RA直接导致的情况下，我们通过所有客观措施观察到淋巴水肿的显着减少和压缩的消除。这也可能会降低患者的BMI，使其成为淋巴静脉搭桥或血管化淋巴结移植的良好候选者。
■术后9个月，患者出现手臂肿胀和残疾。在进行辅助化疗和激素治疗时，她的体重急剧增加，4年后达到顶峰。与她的体重增加相对应的是她的症状的显著恶化。
■由于与癌症相关的辅助性体重增加以及无法通过饮食和运动来减肥，她被转诊接受评估，并被诊断患有淋巴水肿。患者开始使用胰高血糖素样肽1受体激动剂治疗，在接下来的13个月内体重下降了24％。淋巴水肿的改善反映了她的体重减轻。她的肢体体积差异从10.3％下降到3.4％，她不再需要压缩服。她的影像学表现为淋巴泵的恢复，并且生活质量得到了显着改善，由经过验证的淋巴水肿特异性患者报告的结果（PROM）评估。她还在接受荷尔蒙疗法,不再需要压缩，回到正常运动而没有损伤。
GLP-1RA为许多体重增加和淋巴水肿的患者提供了潜在的医疗选择。在GLP-1RA直接导致的情况下，我们通过所有客观措施观察到淋巴水肿的显着减少和压缩的消除。这也可能会降低患者的BMI，使其成为淋巴静脉搭桥或血管化淋巴结移植的良好候选者。
